Other News To Note
Wednesday, December 28, 2011
Arecor Ltd., of Cambridge, UK, entered into a collaboration agreement with Indianapolis-based Eli Lilly and Co. to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs. Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly. In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas. Arecor specializes in stabilization of biologic molecules. Financial terms of the deal were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.